WO2017164659A2 - Method for examining ability of natural material to increase immunocompetence and method for providing customized diet using same - Google Patents

Method for examining ability of natural material to increase immunocompetence and method for providing customized diet using same Download PDF

Info

Publication number
WO2017164659A2
WO2017164659A2 PCT/KR2017/003107 KR2017003107W WO2017164659A2 WO 2017164659 A2 WO2017164659 A2 WO 2017164659A2 KR 2017003107 W KR2017003107 W KR 2017003107W WO 2017164659 A2 WO2017164659 A2 WO 2017164659A2
Authority
WO
WIPO (PCT)
Prior art keywords
cells
antigen
blood
natural material
natural
Prior art date
Application number
PCT/KR2017/003107
Other languages
French (fr)
Korean (ko)
Other versions
WO2017164659A3 (en
Inventor
백강민
Original Assignee
온틀협동조합
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 온틀협동조합 filed Critical 온틀협동조합
Publication of WO2017164659A2 publication Critical patent/WO2017164659A2/en
Publication of WO2017164659A3 publication Critical patent/WO2017164659A3/en

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866Interferon
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells

Definitions

  • the present invention relates to a method for testing an individual's immune capacity by adding antigenic cells to blood of an individual and measuring the killing of antigenic cells and cytokines including IFN- ⁇ .
  • the present invention by adding antigen cells and natural material to the blood of the individual to measure the killing of antigen cells and cytokines including IFN- ⁇ to a method that can examine the extent to which the natural material affects the individual's immune capacity enhancement It is about.
  • the present invention relates to a method for providing a customized diet for enhancing an individual's immunity after identifying and selecting a natural material for enhancing an individual's immunity.
  • the immune system consists of innate and acquired immunity. Congenital immune cells have evolved to take early defense by responding to pathogens with limited receptors, and acquired immune cells are driven by T cells, and have a wider variety of memory and specific responses to specific antigens of infectious organisms. The attack system has evolved to enable immediate and effective response to reinfection of the same pathogens.
  • Innate immune responses are important for inducing early immune responses as well as for determining the direction and intensity of responses.
  • the acquired immune response itself acts to enhance the innate immune response, so that the two immune responses cooperatively form positive feedbacks to cope with infection effectively.
  • Innate immune responses and immunoregulatory cells regulate differentiation of acquired immune responses that is, they are controlled to differentiate into Th1 responses that primarily represent cytotoxic responses or Th2 responses that mainly represent humoral responses, including antibody responses, depending on the nature of the infectious agent. Induces an immune response that is optimal for the removal of infectious organisms.
  • NK cells Natural killer cells
  • cytotoxicity cytotoxicity
  • NK cells play a key role in regulating immune responses through direct interactions with dendritic cells, macrophages, T cells, and indirect interactions with cytokines.
  • This process is outlined as a mechanism by which NK cells are activated by interferons (IFNs) or macrophages-derived cytokines. That is, when exposed to IFN- ⁇ , IFN- ⁇ or IL-12, one of the cytokines produced at the beginning of infection, its activity is amplified 20 to 100 times to produce IFN- ⁇ . In other words, IFN- ⁇ and IFN- ⁇ synergize with IL-12, NK cells produce a large amount of IFN- ⁇ , and this IFN- ⁇ plays an essential role in controlling infection.
  • IFNs interferons
  • NK cells express various germ-line encoded immunoreceptors that induce or inhibit activity instead of lacking an antigen specific receptor. NK cells recognize target cells through these receptors and regulate their activity by a comprehensive signaling balance induced thereby.
  • NKT cells Natural killer T cells
  • Natual killer T cells have less than 1% of the total lymphocytes, but have been known to play an important role in various immune responses and pathologies.
  • NKT is a major cell population that performs multifaceted immunomodulatory functions in a wide range of immune diseases. Many studies of NKT cells in the past have reported that natural or artificial activation of NKT suppresses these diseases in a variety of diseases, including autoimmune diseases, transplant rejection, infectious diseases, and cancer.
  • NKT cells one of the immunoregulatory cells, are a heterogeneous group of T cells. They express NK cell markers, including NK cell receptors, on the cell surface. Unlike conventional T cell selection methods, CD 1d-glycolipid and Expresses the CD 1d-lipid complex. NKT cells are positively selected by CD4 + , CD8 + double positive (DP) thymic cells.
  • NKT cells It has different properties from other cell populations Within a short time With large amounts of IL-4 IFN secretes - ⁇ , Th1 and On Th2 reaction Central variety Cytokine Secrete. As a result, T-cell Th1 Of Th2 Plays an important role in controlling differentiation.
  • ILC innate lymphoid cells
  • ILC innate lymphoid cells
  • congenital lymphocytes do not possess antigen specificity, but they are anatomically similar to T cells and are congenital in that they play a role in T cells. 'S discovery caused a big wave in academia.
  • Congenital lymphocytes respond rapidly to innate cytokines (IL-1, IL-33, IL-25) and are responsible for maintaining tissue homeostasis, repairing damaged tissues, and protecting against pathogens. Although studies on the characteristics and functions of congenital lymphocytes are still underway, congenital lymphocytes can be classified into three groups.
  • Type 1 congenital lymphocytes have a phenotype that is quite similar to natural killer cells. Until recently, natural killer cells were thought to be primitives of congenital lymphocytes, and they were included in ILC1 in a broad sense, but in 2013, type 1 congenital lymphocytes (ILC1) were found in the colon of patients with Crohn's disease. The two are now being studied separately.
  • type 1 congenital lymphocytes Both natural killer cells and type 1 congenital lymphocytes require T-bet, a transcription factor, and secrete IFN- ⁇ in the differentiation process, but type 1 congenital lymphocytes are granzyme secreted by natural killer cells. The difference is that they do not secrete cytotoxic substances such as perforin. Instead, type 1 congenital lymphocytes can secrete large amounts of IFN- ⁇ in response to IL-7 and IL-12 .
  • NK cells natural killer cells
  • NKT cells natural killer T cells
  • ILC congenital lymphocyte cells
  • NK cells natural killer cells
  • NKT cells natural killer T cells
  • IFN- ⁇ congenital lymphocyte cells
  • Korean Patent Publication No. 10-2011-0010030 discloses an 'immunity test system for food selection'.
  • Korean Patent Publication No. 10-2004-0047899 discloses 'a novel method for measuring immunological activity'.
  • the prior art has a similar aspect to the present invention in that it measures immune cells and cytokines, the overall function of antigen cells is not measured by measuring each factor separately, and thus immunity based on innate and acquired immune mechanisms. The ability test can be said to be difficult.
  • the problem to be solved by the present invention is to provide a method for testing an individual's immune capacity by adding antigenic cells to individual blood and measuring the killing of antigenic cells and cytokines including IFN- ⁇ .
  • the problem of the present invention is to add the antigen cells and natural material to the blood of the individual to measure the killing of antigen cells and cytokines including IFN- ⁇ to examine the extent to which the natural material affects the individual's immune capacity enhancement. To provide a way.
  • the problem of the present invention is to provide a method for providing a customized diet for enhancing the individual's immunity after identifying and selecting a natural material for enhancing the individual's immunity.
  • the present invention comprises the steps of: a) collecting blood;
  • step a) culturing by adding antigen cells and natural material to the blood of step a);
  • step d) analyzing the cultured blood in step d) to determine the death of antigen cells and the concentration of cytokines including IFN- ⁇ ;
  • the present invention comprises the steps of performing the steps d) to f) on a plurality of natural products, respectively, analyzing the immune enhancing effect of each natural material; Providing a personalized diet providing method for immunological enhancement, comprising: providing a personalized diet based on the analysis result, to solve the technical problem.
  • the immunoassay method of the natural product material according to the present invention has a remarkable effect of providing an immunocompetence test method based on innate immunity and acquired immune mechanisms by examining the action on antigen cells.
  • NK cells natural killer cells
  • NKT cells natural killer T cells
  • innate lymphoid cells Innate lymphoid cells Holds.
  • the method of providing a customized diet according to the present invention has a remarkable effect of providing an optimal immune enhancing diet for each individual after examining the immune enhancement of each natural material.
  • 1 is a diagram schematically illustrating a method for testing an individual's immune capacity.
  • Figure 2 is a schematic diagram illustrating a method for testing the immune capacity enhancement of natural materials.
  • FIG. 1 is a view schematically showing a method for testing an individual's immune capacity
  • Figure 2 is a diagram schematically showing a method for testing the immune capacity enhancement of a natural material.
  • the sick includes a cancer patient or a person infected with a virus or the like.
  • Antigen cells are added and cultured to normal human blood, and the blood of the sick is cultured according to the characteristics of the antigen cells.
  • the antigen cells to be injected and the antigen cells of the sick are subject to floating cells. This is because adherent cells cannot be used because NK cells are floating cells.
  • the antigen cells to be added may be human cancer cells, preferably K562 cells.
  • K562 cells are a cell line derived from a patient with chronic myelogenous leukemia, and are originally Philaderphia chromosome positive (Ph + ), bcr-Abl positive cells. It shows pluripotent stem cell-like properties that differentiate into erythrocytes, granulocytes, and monocytes upon stimulation.In addition to its use in stem cell research, it has high susceptibility to cytotoxicity by NK cells. Can be.
  • DMEM and RPMI medium containing 10% FBS, 1% penicilin and streptomycin are used for culturing human cancer cells. Measure the number of cells at 1 ⁇ 10 8 cells / mL using a hemocytometer, and incubate in T25 cell culture flasks for 24 hours at 37 ° C., 5%, CO 2 incubator. Subcultures should be done once every two to three days. However, the culture conditions or the duration of the culture may be changed depending on the characteristics of the antigen cells.
  • the cultured blood is analyzed to determine the death of antigen cells and cytokines including IFN- ⁇ .
  • the killing assay of antigen cells can be made by measuring the cell proliferation rate using MTT assay.
  • MTT (3- [4,5-dimethyl thiazol-2-yl] -2,5-yl tetrazolium bromide) assay is a measure of the toxicity and viability of cells.
  • the yellow water-soluble substance MTT is responsible for the dehydrogenase activity in mitochondria. It uses the principle of producing purple formazan that is insoluble in water. To this end, each cell line is added 200 ⁇ L to 96well at the concentration of 1 ⁇ 10 4 cells / well and incubated in 37 ° C., 5% CO 2 incubator for 24 hours to stabilize. Prepared extracts are treated in medium at an appropriate concentration and incubated for 48 hours.
  • MTT (3- [4,5-dimethyl thiazol-2-yl] -2,5-yl tetrazolium bromide) assay reagent was added to the medium and reacted at 37 ° C., 5% CO 2 incubator for 4 hours, followed by MTT reaction solution. Remove it. In order to dissolve the generated formazan, 200 ⁇ L of DMSO was treated and the absorbance was measured at 540 nm with an ELISA spectrometer.
  • the concentration change of cytokines including IFN- ⁇ may be performed by ELISA technique.
  • binding buffer 0.1 M sodium phosphate buffer, pH 9.0
  • blocking buffer 1% BSA / PBS
  • the biotinylated anti-cytokine detection antibody was diluted in blocking buffer / Tween and treated with 100 ⁇ L / well and left at 37 ° C for 1 hour.
  • streptavidin-HRP diluted to 1/1000 was diluted in blocking buffer / Tween at 100 ⁇ g / well and left for 1 hour before washing.
  • the killing of antigen cells is analyzed and the difference between the concentration of cytokines analyzed in the blood of normal humans and the concentration of cytokines after injection of antigen cells is analyzed.
  • the values presented in the medical database may be utilized or a separate reference condition may be prepared to score immunity according to the death of antigen cells and changes in cytokine concentration.
  • step 1-2 Perform the same as in step 1-2) above, but additional natural material is added to the blood.
  • the ingredient of the natural product material may be a herbal preparation or a food preparation or a main ingredient of the food.
  • the natural product material may be an extract or concentrate extracted using hot water, ethanol, fermentation or fractions in the case of herbal preparations, and may be a sample obtained by pulverizing, powdering and dissolving foods in the case of food preparations or main ingredients of foods.
  • step 1-4 Perform the same as in step 1-4), but compare the results of step 1-4) to examine the immune enhancing ability of the natural material. In other words, if the killing of antigen cells and the secretion of cytokines including IFN- ⁇ were increased than the results analyzed in step 1-4), it can be said that the immune enhancing ability of the natural material to be tested was confirmed.
  • the optimal concentration may be analyzed by repeating steps 2-1) to 2-4) according to the concentration of the same natural material.
  • the optimal natural materials may be analyzed.
  • steps 1-1) to 1-4) are performed to measure the individual's immune capacity.
  • steps 2-1) to 2-4) are performed for various natural materials.
  • an optimal natural material for each individual can be selected.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to a method for examining individual subjects for immunocompetence wherein blood samples from individual subjects are added with antigen cells and assayed for the death of the antigen cells and the levels of cytokines including IFN-γ. The present invention relates to a method for examining a degree to which a natural material increases the immunocompetence of individual subjects, wherein blood samples from the individual subjects are added with antigen cells and the natural material and assayed for the death of the antigen cells and the level of cytokines including IFN-γ. The present invention relates to a method for providing customized diets for increasing the immunocompetence of individual subjects, comprising determining and selecting natural materials for immunopotentiating the individual subjects.

Description

천연물 소재의 면역증강 검사법 및 상기 검사법을 활용한 맞춤형 식단 제공방법Immunopotentiation Test of Natural Products and Method of Providing Customized Diet Using the Test Method
본 발명은, 항원세포를 개인의 혈액에 첨가하여 항원세포의 사멸 및 IFN-γ를 포함한 싸이토카인을 측정함으로써 개인의 면역능력을 검사할 수 있는 방법에 관한 것이다.The present invention relates to a method for testing an individual's immune capacity by adding antigenic cells to blood of an individual and measuring the killing of antigenic cells and cytokines including IFN-γ.
본 발명은, 항원세포와 천연물 소재를 개인의 혈액에 첨가하여 항원세포의 사멸 및 IFN-γ를 포함한 싸이토카인을 측정함으로써 천연물 소재가 개인의 면역능력 증강에 영향을 미친 정도를 검사할 수 있는 방법에 관한 것이다.The present invention, by adding antigen cells and natural material to the blood of the individual to measure the killing of antigen cells and cytokines including IFN-γ to a method that can examine the extent to which the natural material affects the individual's immune capacity enhancement It is about.
본 발명은, 개인의 면역능력 증강을 위한 천연물 소재를 확인 선별한 후에, 개인의 면역능력 증강을 위한 맞춤형 식단을 제공하는 방법에 관한 것이다.The present invention relates to a method for providing a customized diet for enhancing an individual's immunity after identifying and selecting a natural material for enhancing an individual's immunity.
면역계는 선천성 면역과 후천성 면역으로 이루어진다. 선천성 면역세포들은 제한된 수용체를 이용하여 병원균에 즉각적으로 반응하여 조기 방어를 담당하도록 진화하였고, 후천성 면역세포들은 T세포에 의해 주도되어지며, 감염균의 특정 항원에 특이적으로 반응하는 기억능력과 더욱 다양한 공격 체계를 갖춰 동일한 병원균들의 재감염시 즉각적이고 효과적인 대처가 가능하도록 진화하였다. The immune system consists of innate and acquired immunity. Congenital immune cells have evolved to take early defense by responding to pathogens with limited receptors, and acquired immune cells are driven by T cells, and have a wider variety of memory and specific responses to specific antigens of infectious organisms. The attack system has evolved to enable immediate and effective response to reinfection of the same pathogens.
선천성 면역반응은 초기 방어뿐만 아니라 후천성 면역반응을 유도하고 반응의 방향과 강도를 결정하는데도 중요한 영양을 미친다. 또한, 후천성 면역반응 자체는 다시 선천성 면역반응을 강화하는 작용을 함으로써 두 면역반응은 서로 협력적으로 양성 피드백을 형성하여 효과적으로 감염에 대응한다.Innate immune responses are important for inducing early immune responses as well as for determining the direction and intensity of responses. In addition, the acquired immune response itself acts to enhance the innate immune response, so that the two immune responses cooperatively form positive feedbacks to cope with infection effectively.
선천성 면역반응과 면역조절세포는 후천성 면역반응을 분화 조절하는데, 즉 감염 병원체의 특성에 따라 세포독성 반응을 주로 나타내는 Th1반응 또는 항체반응을 포함한 체액성 반응을 주로 나타내는 Th2 반응으로 분화되도록 조절하여 해당 감염균의 제거에 최적인 면역반응을 유도한다. Innate immune responses and immunoregulatory cells regulate differentiation of acquired immune responses, that is, they are controlled to differentiate into Th1 responses that primarily represent cytotoxic responses or Th2 responses that mainly represent humoral responses, including antibody responses, depending on the nature of the infectious agent. Induces an immune response that is optimal for the removal of infectious organisms.
자연살해세포(NK cell)는 선천성 면역세포 중의 하나로 암세포에 대해 선택적인 세포독성(cytotoxicity)를 보이는 세포로서 그 존재가 알려졌다. 즉 NK cell은 암세포 및 바이러스에 감염된 세포를 제거하는데 핵심적인 역할을 한다. 또한, 골수 이식, 태아의 착상 및 생식조절에도 중요한 역할을 함이 규명되었다. Natural killer cells (NK cells) , one of the innate immune cells, is known for its cytotoxicity (cytotoxicity) to cancer cells. In other words, NK cells play a key role in removing cancer cells and cells infected with viruses. It has also been found to play an important role in bone marrow transplantation, fetal implantation and fertility control.
더불어 NK cell은 수지상세포(dendritic cell), 대식세포(macrophage), T cell과의 직접적 상호작용 및 싸이토카인(cytokine)을 통한 간접적 상호작용을 통해 면역반응을 조절하는데도 핵심적인 역할을 한다. In addition, NK cells play a key role in regulating immune responses through direct interactions with dendritic cells, macrophages, T cells, and indirect interactions with cytokines.
이 과정을 개략적으로 살펴보면, NK cell이 인터페론(IFN, interferons)이나 대식세포 유래 싸이토카인에 의해 활성화되는 기전으로 설명된다. 즉 감염 초기에 생산되는 싸이토카인 중의 하나인 IFN-α와 IFN-β 또는 IL-12에 노출되었을 때 그 활성도가 20~100배로 증폭되어 IFN-γ를 생산하게 된다. 다시 말해, IFN -α 및 IFN-β는 IL-12와 함께 상호 상승작용을 하여 NK cell이 다량의 IFN -γ을 생산하고 이 IFN -γ이 감염을 조절하는데 필수적인 작용을 하게 되는 것이다. This process is outlined as a mechanism by which NK cells are activated by interferons (IFNs) or macrophages-derived cytokines. That is, when exposed to IFN-α, IFN-β or IL-12, one of the cytokines produced at the beginning of infection, its activity is amplified 20 to 100 times to produce IFN-γ. In other words, IFN- α and IFN-β synergize with IL-12, NK cells produce a large amount of IFN- γ, and this IFN- γ plays an essential role in controlling infection.
또한, NK cell 은 항원 특이적 수용체(receptor)가 없는 대신 활성을 유도하거나 억제하는 생식계열 코딩(germ-line coding)된 다양한 면역수용체를 발현한다. NK cell은 이들 수용체를 통해 표적세포(target cell)을 인식하고 이로써 유도되는 종합적인 신호전달 균형에 의해 그 활성을 조절된다. In addition, NK cells express various germ-line encoded immunoreceptors that induce or inhibit activity instead of lacking an antigen specific receptor. NK cells recognize target cells through these receptors and regulate their activity by a comprehensive signaling balance induced thereby.
자연살해T세포 ( NKT세포 , Natual killer T 세포)는 전체 림프구(lymphocyte)의 1%도 안되는 비율을 가지고 있지만 다양한 면역반응과 병리학 측면에서 중요한 역할을 하는 것으로 알려져 왔다. Natural killer T cells ( NKT cells , Natual killer T cells) have less than 1% of the total lymphocytes, but have been known to play an important role in various immune responses and pathologies.
NKT는 광범위한 면역질환에서 다면적인 면역조절 기능을 수행하는 주요 세포군이다. 과거 NKT세포에 관한 많은 연구들은 자가면역질환, 이식거부반응, 감염성질환, 암 등 다양한 질환에서 NKT의 자연적인 혹은 인위적인 활성화가 이러한 질환들을 억제한다고 보고하였다.NKT is a major cell population that performs multifaceted immunomodulatory functions in a wide range of immune diseases. Many studies of NKT cells in the past have reported that natural or artificial activation of NKT suppresses these diseases in a variety of diseases, including autoimmune diseases, transplant rejection, infectious diseases, and cancer.
면역조절세포 중 하나인 NKT 세포는 T세포의 일부로서 불균질한 그룹이다, NK cell receptor를 포함한 NK cell marker를 세포 표면에 발현하며, 기존의 T세포의 선택 방식과는 달리 CD 1d-glycolipid와 CD 1d-lipid 복합체를 발현한다. NKT세포는 CD4+, CD8+ double positive (DP) 흉선세포들에 의해 양성적으로 선택된다. NKT cells, one of the immunoregulatory cells, are a heterogeneous group of T cells. They express NK cell markers, including NK cell receptors, on the cell surface. Unlike conventional T cell selection methods, CD 1d-glycolipid and Expresses the CD 1d-lipid complex. NKT cells are positively selected by CD4 + , CD8 + double positive (DP) thymic cells.
NKT세포는NKT cells 다른 세포군들과 다른 특이적인 성질을 가지고 있는데  It has different properties from other cell populations 빠른 시간 내에Within a short time 다량의 IL-4와  With large amounts of IL-4 IFNIFN -γ를 분비하며, secretes -γ, Th1과Th1 and Th2반응에On Th2 reaction 중심이 되는 다양한  Central variety 싸이토카인을Cytokine 분비한다. 그 결과에 따라,  Secrete. As a result, T세포의T-cell Th1Th1 /Of Th2의Th2 분화를 조절하는데 중요한 역할을 담당한다. Plays an important role in controlling differentiation.
ILC (innate lymphoid cells, 선천성 림프구 세포)는 2010년도에 새롭게 발견된 세포군으로서 T세포 수용체(T cell receptor)나 B세포 수용체(B cell receptor)와 같은 항원 수용체가 없으면서 형태학적으로 림프구 계열 세포의 특징을 지닌 세포군이다. ILC (innate lymphoid cells) is a newly discovered cell population in 2010 that is characterized by the morphological characteristics of lymphoid cells without the presence of antigen receptors such as T cell receptors or B cell receptors. Cell group with
후천성 면역반응을 담당하고 있는 T 세포와는 달리 선천성 림프구 세포는 항원 특이성을 보유하고 있지 않지만, 해부학적인 측면에서 T 세포와 비슷한 형태를 가지고 있으며 T 세포에 상응하는 역할을 담당한다는 점에서 선천성 림프구 세포의 발견은 학계에서 큰 파장을 일으켰다. Unlike T cells, which are responsible for the acquired immune response, congenital lymphocytes do not possess antigen specificity, but they are anatomically similar to T cells and are congenital in that they play a role in T cells. 'S discovery caused a big wave in academia.
선천성 림프구 세포는 주로 선천성 사이토카인(IL-1, IL-33, IL-25)에 빠르 게 반응하며, 조직의 항상성 유지, 손상조직의 복구 및 병원체로부터의 방어반응 등을 담당하고 있다. 아직까지도 선천성 림프구 세포의 특성과 기능에 대한 연구는 진행되고 있는 상태이지만, 선천성 림프구 세포는 크게 3개의 그룹으로 분류할 수 있다. Congenital lymphocytes respond rapidly to innate cytokines (IL-1, IL-33, IL-25) and are responsible for maintaining tissue homeostasis, repairing damaged tissues, and protecting against pathogens. Although studies on the characteristics and functions of congenital lymphocytes are still underway, congenital lymphocytes can be classified into three groups.
Type 1 선천성 림프구 세포(ILC1)는 자연살해세포와 상당히 유사한 표현형을 보인다. 아주 최근까지도 자연살해세포가 선천성 림프구 세포의 원시형으로 생각되고, 자연살해세포가 넓은 의미에서 ILC1에 포함되었지만, 2013년에 크론씨병을 가지고 있는 환자의 대장에서 type 1 선천성 림프구 세포(ILC1)가 발견되었기 때문 에 이제는 이 둘을 구분지어 연구되고 있다. Type 1 congenital lymphocytes (ILC1) have a phenotype that is quite similar to natural killer cells. Until recently, natural killer cells were thought to be primitives of congenital lymphocytes, and they were included in ILC1 in a broad sense, but in 2013, type 1 congenital lymphocytes (ILC1) were found in the colon of patients with Crohn's disease. The two are now being studied separately.
자연살해세포와 type 1 선천성 림프구 세포는 모두 분화 과정에서 전사인자인 T-bet을 필요로 하고, IFN-γ를 분비한다는 공통점을 가지고 있지만, type 1 선천성 림프구 세포는 자연살해세포가 분비하는 granzyme이나 perforin과 같은 세포 독성을 가지고 있는 물질을 분비하지 못한다는 차이점을 가지고 있다. 대신 type 1 선천성 림프구 세포는 IL-7과 IL-12에 반응하여 다량의 IFN -γ를 분비할 수 있다. Both natural killer cells and type 1 congenital lymphocytes require T-bet, a transcription factor, and secrete IFN-γ in the differentiation process, but type 1 congenital lymphocytes are granzyme secreted by natural killer cells. The difference is that they do not secrete cytotoxic substances such as perforin. Instead, type 1 congenital lymphocytes can secrete large amounts of IFN- γ in response to IL-7 and IL-12 .
따라서 혈액 속에 존재하는 자연살해세포(NK cell), 자연살해T세포(NKT cell), 선천성 림프구 세포(ILC)를 분석함으로써 개인의 면역능력 및 활성도를 분석한 후 이를 통해 현재의 건강상태를 확인할 수 있다고 하겠다.Therefore, by analyzing natural killer cells (NK cells), natural killer T cells (NKT cells) and congenital lymphocyte cells (ILC) present in the blood, the current health status can be confirmed by analyzing the individual's immune capacity and activity. I would say.
본 출원인은 자연살해세포(NK cell), 자연살해T세포(NKT cell) 및 선천성 림프구 세포(ILC)가 다양한 싸이토카인을 분비하고 상호 작용하지만 특히 IFN-γ를 분비하여 면역을 조절한다는 점에 착안하여 본 발명을 안출하였다.Applicants focus on the fact that natural killer cells (NK cells), natural killer T cells (NKT cells) and congenital lymphocyte cells (ILCs) secrete and interact with various cytokines, but specifically secrete IFN-γ to regulate immunity. The present invention has been devised.
(1) 항원세포를 개인의 혈액에 주입하여 항원세포의 사멸 및 IFN-γ를 포함한 싸이토카인을 측정함으로써 개인의 면역능력을 검사할 수 있다는 점을 착안하였다.(1) It was conceived that an individual's immune capacity can be tested by injecting antigen cells into the blood of an individual and measuring the death of antigen cells and cytokines including IFN-γ.
(2) 항원세포와 천연물 소재를 개인의 혈액에 첨가하여 항원세포의 사멸 및 IFN-γ를 포함한 싸이토카인을 측정함으로써 천연물 소재가 (1)에서 측정한 면역능력에 영향을 미치는지 여부를 검사할 수 있다는 점을 착안하였다.(2) It is possible to test whether natural material affects the immune ability measured in (1) by adding antigen cells and natural material to individual's blood and measuring the death of antigen cells and cytokines including IFN-γ. The point was focused.
(3) (1)과 (2)의 과정을 통해 개인의 면역능력 증강을 위한 천연물 소재를 확인 선별한 후에, 개인의 면역능력 증강을 위한 맞춤형 식단을 제공할 수 있다는 점을 착안하였다. (3) After identifying and screening natural materials for enhancing the individual's immunity through the process of (1) and (2), it was conceived that a customized diet for enhancing the individual's immunity can be provided.
이하, 본 발명과 관련된 선행기술에 대하여 간략하게 살펴본다. 첫 번째로, 대한민국 공개특허공보 제10-2011-0010030호에는 '식품 선택을 위한 면역검사시스템'이 기재되어 있다.Hereinafter, a brief look at the prior art related to the present invention. First, Korean Patent Publication No. 10-2011-0010030 discloses an 'immunity test system for food selection'.
개략적으로 살펴보면, 개인의 혈액을 채취하고, 채취된 혈액으로부터 면역세포를 분리, 검사하여 면역세포의 활성을 측정하는 단계; 상기 면역세포에 다양한 식품을 주입하고 배양하는 단계; 상기 배양세포를 검사하여 활성을 측정하고 식품별 개선효과를 확인하는 단계; 개인별로 면역력에 효과를 보이는 최적의 식품을 선택하여 주는 단계를 포함한다.Schematically, collecting the blood of the individual, separating and testing the immune cells from the collected blood to measure the activity of the immune cells; Injecting and culturing various foods into the immune cells; Inspecting the cultured cells to measure activity and confirm improvement effects for each food; It includes the step of selecting the best foods that have an effect on the immunity for each individual.
그런데 상기 선행기술은 실질적으로 항원세포에 대한 작용성을 검사하지 않음으로써 선천성 면역과 후천성 면역 기전에 근거한 면역능력 검사는 이루어지기 어렵다고 할 수 있다. 또한, 특정 면역세포를 분리 배양하기 때문에 검사방법 면에서도 효율성 문제가 제기될 수 있다. However, since the prior art does not substantially test the function on antigen cells, it is difficult to test immunity based on innate immunity and acquired immune mechanism. In addition, because the specific immune cells are isolated and cultured, efficiency problems may be raised in terms of test methods.
두 번째로, 대한민국 공개특허공보 제10-2004-0047899호에는 '신규한 면역활성 측정방법'이 기재되어 있다.Secondly, Korean Patent Publication No. 10-2004-0047899 discloses 'a novel method for measuring immunological activity'.
개략적으로 살펴보면, NKT 세포, NK세포, CD8, perforin 생산세포, IL-12 및 IFN-γ의 측정방법들이 상세한 설명에 제시되어 있다.In brief, methods for measuring NKT cells, NK cells, CD8, perforin producing cells, IL-12 and IFN-γ are shown in the detailed description.
상기 선행기술은 면역세포와 싸이토카인을 측정한다는 점에서 본 출원발명과 유사한 면이 존재하나, 각 인자를 별도로 측정함으로써 항원세포에 총괄적인 작용성이 측정되지 않는바 선천성 면역과 후천성 면역 기전에 근거한 면역능력 검사는 이루어지기 어렵다고 할 수 있다.Although the prior art has a similar aspect to the present invention in that it measures immune cells and cytokines, the overall function of antigen cells is not measured by measuring each factor separately, and thus immunity based on innate and acquired immune mechanisms. The ability test can be said to be difficult.
본 발명의 해결과제는 항원세포를 개인의 혈액에 첨가하여 항원세포의 사멸 및 IFN-γ를 포함한 싸이토카인을 측정함으로써 개인의 면역능력을 검사할 수 있는 방법을 제공하는 것이다.The problem to be solved by the present invention is to provide a method for testing an individual's immune capacity by adding antigenic cells to individual blood and measuring the killing of antigenic cells and cytokines including IFN-γ.
본 발명의 해결과제는 항원세포와 천연물 소재를 개인의 혈액에 첨가하여 항원세포의 사멸 및 IFN-γ를 포함한 싸이토카인을 측정함으로써 천연물 소재가 개인의 면역능력 증강에 영향을 미친 정도를 검사할 수 있는 방법을 제공하는 것이다.The problem of the present invention is to add the antigen cells and natural material to the blood of the individual to measure the killing of antigen cells and cytokines including IFN-γ to examine the extent to which the natural material affects the individual's immune capacity enhancement. To provide a way.
본 발명의 해결과제는 개인의 면역능력 증강을 위한 천연물 소재를 확인 선별한 후에, 개인의 면역능력 증강을 위한 맞춤형 식단을 제공하는 방법을 제공하는 것이다. The problem of the present invention is to provide a method for providing a customized diet for enhancing the individual's immunity after identifying and selecting a natural material for enhancing the individual's immunity.
본 발명은, a) 혈액을 채취하는 단계;The present invention comprises the steps of: a) collecting blood;
b) 상기 혈액에 항원세포를 첨가하여 배양하는 단계;b) culturing by adding antigen cells to the blood;
c) 상기 배양이 끝난 혈액을 분석하여 항원세포의 사멸 및 IFN-γ를 포함한 싸이토카인의 농도를 측정하는 단계;c) analyzing the cultured blood and measuring the concentration of cytokines including killing of antigen cells and IFN-γ;
d) 상기 a)단계의 혈액에 항원세포 및 천연물 소재를 첨가하여 배양하는 단계;d) culturing by adding antigen cells and natural material to the blood of step a);
e) 상기 d) 단계에서 배양이 끝난 혈액을 분석하여 항원세포의 사멸 및 IFN-γ를 포함한 싸이토카인의 농도를 측정하는 단계; 및e) analyzing the cultured blood in step d) to determine the death of antigen cells and the concentration of cytokines including IFN-γ; And
f) 상기 c) 단계의 측정 결과와 상기 e) 단계의 측정 결과를 비교 분석하는 단계;를 포함하는, 천연물 소재의 면역증강을 검사하는 방법을 제공함으로써, 기술적 과제를 해결하고자 한다.Comprising: f) comparing the measurement results of step c) and the measurement results of step e); to provide a method for testing the immune augmentation of natural materials, to solve the technical problem.
본 발명은, 상기 d)~f) 단계를 복수 개의 천연물 소재에 각각 수행하여 천연물 소재 각각의 면역증강 효과를 분석하는 단계; 및 상기 분석 결과에 기초하여 개인별 맞춤형 식단을 제공하는 단계;를 포함하는, 면역증강을 위한 맞춤형 식단 제공방법을 제공함으로써, 기술적 과제를 해결하고자 한다.The present invention comprises the steps of performing the steps d) to f) on a plurality of natural products, respectively, analyzing the immune enhancing effect of each natural material; Providing a personalized diet providing method for immunological enhancement, comprising: providing a personalized diet based on the analysis result, to solve the technical problem.
본 발명에 따른 천연물 소재의 면역증강 검사법은, 항원세포에 대한 작용성을 검사함으로써 선천성 면역과 후천성 면역 기전에 근거한 면역능력 검사방법을 제공할 수 있는 현저한 효과를 보유하고 있다.The immunoassay method of the natural product material according to the present invention has a remarkable effect of providing an immunocompetence test method based on innate immunity and acquired immune mechanisms by examining the action on antigen cells.
본 발명에 따른 천연물 소재의 면역증강 검사법은, 자연살해세포(NK cell), 자연살해T세포(NKT cell) 및 선천성 림프구 세포(Innate lymphoid cell)의 활성도 증강을 포함하여 검사할 수 있는 현저한 효과를 보유하고 있다.Immunoassay of natural products according to the present invention, the remarkable effects that can be examined including the enhanced activity of natural killer cells (NK cells), natural killer T cells (NKT cells) and innate lymphoid cells (Innate lymphoid cells) Holds.
본 발명에 따른 맞춤형 식단 제공방법은, 천연물 소재 각각의 면역증강을 검사한 후에 개인별로 최적의 면역증강 식단을 제공할 수 있는 현저한 효과를 보유하고 있다.The method of providing a customized diet according to the present invention has a remarkable effect of providing an optimal immune enhancing diet for each individual after examining the immune enhancement of each natural material.
도 1은 개인의 면역능력을 검사하는 방법을 개략적으로 도시한 도면이다.1 is a diagram schematically illustrating a method for testing an individual's immune capacity.
도 2는 천연물 소재의 면역능력 증강을 검사하는 방법을 개략적으로 도시한 도면이다.Figure 2 is a schematic diagram illustrating a method for testing the immune capacity enhancement of natural materials.
실시예Example 1. 천연물 소재의 면역증강 검사법 1. Immunopotentiation Test of Natural Products
도 1은 개인의 면역능력을 검사하는 방법을 개략적으로 도시한 도면이고, 도 2는 천연물 소재의 면역능력 증강을 검사하는 방법을 개략적으로 도시한 도면이다.1 is a view schematically showing a method for testing an individual's immune capacity, Figure 2 is a diagram schematically showing a method for testing the immune capacity enhancement of a natural material.
1) 개인의 면역능력을 검사하는 단계1) testing the individual's immune capacity
1-1) 혈액 채취 단계1-1) Blood Collection Step
정상인 혹은 병자의 혈액을 채취한다. 여기에서, 병자는 암환자이거나 바이러스 등에 감염이 된 사람을 포함한다.Collect blood from a healthy person or sick person. Here, the sick includes a cancer patient or a person infected with a virus or the like.
1-2) 혈액에 항원세포를 첨가하여 배양하는 단계1-2) culturing by adding antigenic cells to blood
정상인의 혈액에는 항원세포를 첨가하고 배양을 하며, 병자의 혈액은 해당 항원세포의 특성에 맞게끔 배양을 한다. 여기에서, 주입되는 항원세포나 병자의 항원세포는 부유세포일 것을 조건으로 한다. 왜냐하면 NK cell이 부유세포이기 때문에 부착세포를 사용할 수 없기 때문이다.Antigen cells are added and cultured to normal human blood, and the blood of the sick is cultured according to the characteristics of the antigen cells. The antigen cells to be injected and the antigen cells of the sick are subject to floating cells. This is because adherent cells cannot be used because NK cells are floating cells.
예를 들어, 첨가되는 항원세포는 휴먼 암세포일 수 있고, 바람직하게는 K562 cells일 수 있다. K562 세포는 만성골수성백혈병(慢性骨髓性白血病) 환자 유래 세포주(株)인데 원래는 필라데르피아(Philaderphia)염색체(染色體) 양성(Ph), bcr-Abl양성세포이다. 자극에 따라 적혈구, 과립구, 단구(單球) 등으로 분화하는 다능성 줄기세포 유사 성질을 보여서 줄기세포연구에 사용하는 외에도 NK 세포에 의한 세포상해성에 대한 감수성이 높아 NK 세포활성의 측정에도 이용될 수 있다.For example, the antigen cells to be added may be human cancer cells, preferably K562 cells. K562 cells are a cell line derived from a patient with chronic myelogenous leukemia, and are originally Philaderphia chromosome positive (Ph + ), bcr-Abl positive cells. It shows pluripotent stem cell-like properties that differentiate into erythrocytes, granulocytes, and monocytes upon stimulation.In addition to its use in stem cell research, it has high susceptibility to cytotoxicity by NK cells. Can be.
또한, 휴먼 암세포 배양을 위해서는 10% FBS와 1% penicilin 및 streptomycin이 포함된 DMEM 및 RPMI 배지를 사용한다. hemocytometer를 이용하여 세포수를 1×108 cell/mL로 측정하고, T25 cell culture flasks에 24시간동안 37℃, 5%, CO2 항온기에서 배양한다. 계대배양은 2~3일에 한번씩 시행한다. 그러나 배양조건이나 배양기간은 항원세포의 특성에 따라 변경될 수 있다.In addition, DMEM and RPMI medium containing 10% FBS, 1% penicilin and streptomycin are used for culturing human cancer cells. Measure the number of cells at 1 × 10 8 cells / mL using a hemocytometer, and incubate in T25 cell culture flasks for 24 hours at 37 ° C., 5%, CO 2 incubator. Subcultures should be done once every two to three days. However, the culture conditions or the duration of the culture may be changed depending on the characteristics of the antigen cells.
1-3) 세포사멸능력 및 싸이토카인 측정단계1-3) Cell death ability and cytokine measurement step
배양이 끝난 혈액을 분석하여 항원세포의 사멸 및 IFN-γ를 포함한 싸이토카인을 측정한다.The cultured blood is analyzed to determine the death of antigen cells and cytokines including IFN-γ.
항원세포의 사멸 분석은 MTT assay를 이용한 세포증식률의 측정으로 이루어질 수 있다.The killing assay of antigen cells can be made by measuring the cell proliferation rate using MTT assay.
MTT (3-〔4,5-dimethyl thiazol-2-yl〕-2,5-yl tetrazolium bromide) assay는 세포의 독성과 생존율을 측정하는 방법으로서 황색의 수용성 물질인 MTT가 미토콘드리아 내의 탈수소효소 작용에 의하여 비수용성인 보라색 formazan을 생성하는 원리를 이용한다. 이를 위해 각 세포주를 1×104 cells/well의 농도로 96well에 각각 200μL씩 첨가하여 24시간 동안 37℃, 5% CO2 incubator에서 배양하여 안정화 시킨다. 준비된 추출물을 배지에 적정 농도로 처리하고 48시간 동안 배양한다. 배지에 MTT(3-〔4,5-dimethyl thiazol-2-yl〕-2,5-yl tetrazolium bromide) assay 시약을 처리하여 4시간동안 37℃, 5% CO2 incubator에서 반응시킨 후 MTT 반응 용액을 제거한다. 생성된 formazan을 녹이기 위해 200μL DMSO를 처리하여 ELISA 분광기기로 540nm에서 흡광도를 측정한다.MTT (3- [4,5-dimethyl thiazol-2-yl] -2,5-yl tetrazolium bromide) assay is a measure of the toxicity and viability of cells. The yellow water-soluble substance MTT is responsible for the dehydrogenase activity in mitochondria. It uses the principle of producing purple formazan that is insoluble in water. To this end, each cell line is added 200μL to 96well at the concentration of 1 × 10 4 cells / well and incubated in 37 ° C., 5% CO 2 incubator for 24 hours to stabilize. Prepared extracts are treated in medium at an appropriate concentration and incubated for 48 hours. MTT (3- [4,5-dimethyl thiazol-2-yl] -2,5-yl tetrazolium bromide) assay reagent was added to the medium and reacted at 37 ° C., 5% CO 2 incubator for 4 hours, followed by MTT reaction solution. Remove it. In order to dissolve the generated formazan, 200 μL of DMSO was treated and the absorbance was measured at 540 nm with an ELISA spectrometer.
또한, IFN-γ를 포함한 싸이토카인의 농도변화는 ELISA 기법에 의하여 수행될 수 있다. 96 well plate에 purified anti-human cytokines( IFN-γ) monoclonal antibody를 2 μg/mL로 binding buffer(0.1 M sodium phosphate buffer, pH 9.0)에 희석해서 50 μL/well로 넣은 후, 4℃에서 하룻밤 방치한다. PBS/Tween으로 세척 후, blocking buffer(1% BSA/PBS)를 200 μL/well로 가한 후, 37℃에서 2시간 동안 방치한다. 세척 후, standard cytokine과 추출물을 처리하여 수거한 상층액을 100 μL씩 넣고, 4℃에서 하룻밤 방치한다. PBS/Tween으로 세척 후, biotinylated anti-cytokine detection antibody를 blocking buffer/Tween에 희석하여 100 μL/well로 처리 후 37℃에서 1시간 동안 방치한다. 다시 PBS/Tween으로 세척 후, 1/1000로 희석한 streptavidin-HRP을 100 μg/well로 blocking buffer/Tween에 희석하여 넣고 1시간 방치 후, 세척한다. TMB solution을 100μg/well로 넣고 15분 후, stop reagent로 1 M HCl을 50 μL/well로 넣어, 450 nm에서 ELISA 분광기기로 흡광도를 측정한다. In addition, the concentration change of cytokines including IFN-γ may be performed by ELISA technique. Dilute purified anti-human cytokines (IFN-γ) monoclonal antibodies in a 96 well plate at 2 μg / mL in binding buffer (0.1 M sodium phosphate buffer, pH 9.0), 50 μL / well, and leave at 4 ° C overnight. do. After washing with PBS / Tween, blocking buffer (1% BSA / PBS) was added to 200 μL / well and left at 37 ° C. for 2 hours. After washing, 100 μL of the supernatant collected by treating with standard cytokine and extracts was left at 4 ° C. overnight. After washing with PBS / Tween, the biotinylated anti-cytokine detection antibody was diluted in blocking buffer / Tween and treated with 100 μL / well and left at 37 ° C for 1 hour. After washing with PBS / Tween again, streptavidin-HRP diluted to 1/1000 was diluted in blocking buffer / Tween at 100 μg / well and left for 1 hour before washing. 15 minutes after the TMB solution was added at 100 μg / well, 1 M HCl was added at 50 μL / well as a stop reagent, and the absorbance was measured at 450 nm using an ELISA spectrometer.
설계조건에 따라, 항원세포의 사멸 및 IFN-γ를 포함한 싸이토카인을 측정하는 기법은 다른 방법이 사용될 수도 있다.Depending on design conditions, other methods may be used for techniques for measuring the killing of antigen cells and cytokines including IFN-γ.
1-4) 면역능력 검사 단계1-4) Immunity test step
항원세포의 사멸을 분석하고, 정상인의 혈액에서 분석되는 싸이토카인의 농도와 항원세포가 주입된 후의 싸이토카인 농도의 차이를 분석한다.The killing of antigen cells is analyzed and the difference between the concentration of cytokines analyzed in the blood of normal humans and the concentration of cytokines after injection of antigen cells is analyzed.
이 후에, 의학적 데이터베이스에서 제시하고 있는 수치를 활용하거나 또는, 별도의 기준 조건을 마련하여 항원세포의 사멸과 싸이토카인 농도변화에 따른 면역능력을 점수화할 수 있다.Subsequently, the values presented in the medical database may be utilized or a separate reference condition may be prepared to score immunity according to the death of antigen cells and changes in cytokine concentration.
2) 천연물 소재의 면역증강을 검사하는 단계2) step of examining the immune enhancement of natural products
2-1) 혈액 채취 단계2-1) Blood Collection Step
상기의 1-1) 단계와 동일하게 수행한다.The same procedure as in 1-1) above is performed.
2-2) 혈액에 항원세포 및 천연물 소재를 주입하여 배양하는 단계2-2) incubating antigen cells and natural material into blood
상기의 1-2) 단계와 동일하게 수행하되, 천연물 소재를 추가로 혈액에 첨가한다.Perform the same as in step 1-2) above, but additional natural material is added to the blood.
여기에서, 천연물 소재의 성분은 생약 제제이거나 또는 식품 제제이거나 또는 식품의 주요성분일 수 있다. 천연물 소재는 생약 제제의 경우에는 열수, 에탄올, 발효 또는 분획 등을 활용하여 추출한 추출물 또는 농축물일 수 있으며, 식품 제제나 또는 식품의 주요성분일 경우에는 식품을 분쇄, 분말 및 용해한 시료일 수 있다.Here, the ingredient of the natural product material may be a herbal preparation or a food preparation or a main ingredient of the food. The natural product material may be an extract or concentrate extracted using hot water, ethanol, fermentation or fractions in the case of herbal preparations, and may be a sample obtained by pulverizing, powdering and dissolving foods in the case of food preparations or main ingredients of foods.
2-3) 세포사멸능력 및 싸이토카인 측정단계2-3) Apoptosis and Cytokine Measurement
상기의 1-3) 단계와 동일하게 수행한다.Perform the same procedure as in step 1-3).
2-4) 면역증강을 검사하는 단계2-4) Examination of Immune Enhancement
상기의 1-4) 단계와 동일하게 수행하되, 1-4) 단계의 결과와 비교 분석함으로써 천연물 소재의 면역 증강 능력을 검사한다. 즉, 1-4) 단계에서 분석된 결과보다 항원세포의 사멸과 IFN-γ를 포함한 싸이토카인의 분비가 증가하였다면, 검사대상인 천연물 소재의 면역 증강 능력이 확인되었다고 볼 수 있다.Perform the same as in step 1-4), but compare the results of step 1-4) to examine the immune enhancing ability of the natural material. In other words, if the killing of antigen cells and the secretion of cytokines including IFN-γ were increased than the results analyzed in step 1-4), it can be said that the immune enhancing ability of the natural material to be tested was confirmed.
이 후에는, 동일한 천연물 소재의 농도에 따라 2-1) 내지 2-4) 단계를 반복 수행하여 최적의 농도를 분석할 수 있다.After this, the optimal concentration may be analyzed by repeating steps 2-1) to 2-4) according to the concentration of the same natural material.
또한, 복수 개의 천연물 소재에 대해서 동일한 조건으로 2-1) 내지 2-4) 단계를 수행함으로써 최적의 천연물 소재를 분석할 수 있게 된다. In addition, by performing steps 2-1) to 2-4) under the same conditions on the plurality of natural materials, the optimal natural materials may be analyzed.
실시예Example 2. 천연물 소재의 면역증강 검사법을 활용한 맞춤형 식단 제공방법 2. How to provide a customized diet using natural immunoassay
실시예 1에 따라, 1-1) 내지 1-4) 단계를 수행하여 개인의 면역능력을 측정한다. 여러 가지 천연물 소재에 대한 2-1) 내지 2-4) 단계를 반복 수행함으로써 면역증강을 이룰 수 있는 개인별 최적의 천연물 소재를 선별한다. 이 후에는 상기 선별된 천연물 소재를 이용하여 개인별 맞춤형 식단을 제공한다.According to Example 1, steps 1-1) to 1-4) are performed to measure the individual's immune capacity. By repeating steps 2-1) to 2-4) for various natural materials, an optimal natural material for each individual can be selected. Thereafter, using the selected natural product material to provide a personalized diet.

Claims (5)

  1. a) 혈액을 채취하는 단계;a) collecting blood;
    b) 상기 혈액에 항원세포를 주입하여 배양하는 단계;b) injecting the antigen cells into the blood and culturing;
    c) 상기 배양이 끝난 혈액을 분석하여 항원세포의 사멸 및 IFN-γ를 포함한 싸이토카인의 농도를 측정하는 단계;c) analyzing the cultured blood and measuring the concentration of cytokines including killing of antigen cells and IFN-γ;
    d) 상기 a)단계의 혈액에 항원세포 및 천연물 소재를 첨가하여 배양하는 단계;d) culturing by adding antigen cells and natural material to the blood of step a);
    e) 상기 d) 단계에서 배양이 끝난 혈액을 분석하여 항원세포의 사멸 및 IFN-γ를 포함한 싸이토카인의 농도를 측정하는 단계; 및e) analyzing the cultured blood in step d) to determine the death of antigen cells and the concentration of cytokines including IFN-γ; And
    f) 상기 c) 단계의 측정 결과와 상기 e) 단계의 측정 결과를 비교 분석하는 단계;를 포함하는, 천연물 소재의 면역증강을 검사하는 방법.and f) comparing the measurement result of step c) with the measurement result of step e).
  2. 청구항 1에 있어서,The method according to claim 1,
    상기 혈액이 병자의 혈액일 경우에는 상기 b) 단계와 d) 단계에서 항원세포를 첨가하지 않는 것을 특징으로 하는, 천연물 소재의 면역증강을 검사하는 방법.When the blood is the blood of the sick, steps of b) and d) characterized in that the antigen cells are not added, the method for testing the immune enhancement of the natural material.
  3. 청구항 1에 있어서,The method according to claim 1,
    상기 항원세포는 부유세포인 것을 특징으로 하는, 천연물 소재의 면역증강을 검사하는 방법.The antigen cell is characterized in that the floating cells, a method for examining the immune enhancement of the natural material.
  4. 청구항 1에 있어서,The method according to claim 1,
    상기 천연물 소재의 면역증강은, 자연살해세포(NK cell), 자연살해T세포(NKT cell) 및 선천성 림프구 세포(Innate lymphoid cell)의 활성도 증강을 포함하는 것을 특징으로 하는, 천연물 소재의 면역증강을 검사하는 방법.Immunity enhancement of the natural material, characterized in that to enhance the activity of natural killer cells (NK cells), natural killer T cells (NKT cells) and innate lymphoid cells (Innate lymphoid cells), How to check.
  5. 청구항 1에 기재된 d)~f) 단계를 복수 개의 천연물 소재에 각각 수행하여 천연물 소재 각각의 면역증강 효과를 분석하는 단계; 및 상기 분석 결과에 기초하여 개인별 맞춤형 식단을 제공하는 단계;를 포함하는, 면역증강을 위한 맞춤형 식단 제공방법.Analyzing the immuno-enhancing effect of each natural material by performing steps d) to f) of each of the natural material; And providing a personalized diet based on the analysis result.
PCT/KR2017/003107 2016-03-23 2017-03-23 Method for examining ability of natural material to increase immunocompetence and method for providing customized diet using same WO2017164659A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160034495A KR20170110297A (en) 2016-03-23 2016-03-23 A method for examining the reinforcement of immunization of natural material, and a method for providing personalized diet thereby
KR10-2016-0034495 2016-03-23

Publications (2)

Publication Number Publication Date
WO2017164659A2 true WO2017164659A2 (en) 2017-09-28
WO2017164659A3 WO2017164659A3 (en) 2018-09-07

Family

ID=59900515

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/003107 WO2017164659A2 (en) 2016-03-23 2017-03-23 Method for examining ability of natural material to increase immunocompetence and method for providing customized diet using same

Country Status (2)

Country Link
KR (1) KR20170110297A (en)
WO (1) WO2017164659A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230135111A1 (en) * 2021-11-03 2023-05-04 Samuel B. Reichberg Test to Predict and Evaluate Innate Immune Responses to Infections and Methods of Treatment Thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101981146B1 (en) * 2018-03-26 2019-05-22 충남대학교산학협력단 Method for Evaluating Immune-Boosting Effect and Screening Immunity Materials Using Dendritic Cells
KR101981147B1 (en) * 2018-09-27 2019-05-22 충남대학교산학협력단 Method for Evaluating Immunostimulation Effect of Immuno Materials Using Dendritic Cell and Screening Immuno Materials

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040047899A (en) * 2002-10-08 2004-06-05 오리엔트 캔서 세라피 컴퍼니 리미티드 Novel method of assaying immune activity
AU2002952548A0 (en) * 2002-11-08 2002-11-21 Cellestis Limited Diagnostic assay
JP4359684B2 (en) * 2003-09-17 2009-11-04 独立行政法人農業・食品産業技術総合研究機構 Test method for Johne's disease
KR20110010030A (en) * 2009-07-23 2011-01-31 주식회사 해림후코이단 Immunoassay system

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230135111A1 (en) * 2021-11-03 2023-05-04 Samuel B. Reichberg Test to Predict and Evaluate Innate Immune Responses to Infections and Methods of Treatment Thereof
WO2023081291A1 (en) * 2021-11-03 2023-05-11 Reichberg Samuel Test to predict and evaluate innate immune responses to infections and methods of treatment thereof

Also Published As

Publication number Publication date
WO2017164659A3 (en) 2018-09-07
KR20170110297A (en) 2017-10-11

Similar Documents

Publication Publication Date Title
Grogan et al. Elevated proliferation and interleukin‐4 release from CD4+ cells after chemotherapy in human Schistosoma haematobium infection
Cooper et al. Impaired tetanus-specific cellular and humoral responses following tetanus vaccination in human onchocerciasis: a possible role for interleukin-10
Evans et al. Detection, isolation, and functional characterization of two human T-cell subclasses bearing unique differentiation antigens.
Ngom et al. Improved thymic function in exclusively breastfed infants is associated with higher interleukin 7 concentrations in their mothers' breast milk
Liu et al. Evaluating the effects of immunosuppressants on human immunity using cytokine profiles of whole blood
Clerici et al. Single-cell analysis of cytokine production shows different immune profiles in multiple sclerosis patients with active or quiescent disease
Maes et al. In vitro immunoregulatory effects of lithium in healthy volunteers
Izzo et al. Variation in interferon-gamma responses to Coxiella burnetii antigens with lymphocytes from vaccinated or naturally infected subjects
Strasser et al. Immune modulation following immunization with polyvalent vaccines in dogs
WO2017164659A2 (en) Method for examining ability of natural material to increase immunocompetence and method for providing customized diet using same
Takagi et al. Immune activation and radioprotection by propolis
Mhatre et al. Rapid flow cytometry based cytotoxicity assay for evaluation of NK cell function
Qin et al. CysLT1R expression on ILC2s and effects of CysLT1R antagonist on ILC2 activity in patients with allergic rhinitis.
Schnabel et al. Influences of age and sex on leukocytes of healthy horses and their ex vivo cytokine release
Hu et al. Changes of CD4+ CD25+ regulatory T cells in patients with acute coronary syndrome and the effects of atorvastatin
WO2020067648A2 (en) Method for evaluating immunity enhancement effect of immunogenic material by using dendritic cells, and method for screening for immunogenic material
Brand et al. Immunological responsiveness of intestinal tissue explants and mucosal mononuclear cells to ex vivo stimulation
WONGTAVATCHAI et al. In vitro characteristics of the microsporidian: Enterocytozoon salmonis
WO2014173858A1 (en) Methods for stimulating antigen-specific t cell responses
Hughes et al. Antigen specific lymphocyte transformation induced by secreted antigens from Toxoplasma gondii.
RU2523418C1 (en) Method of assessment of disorder of cellular immunity in exposed to phenol
Frisullo et al. The persistency of high levels of pSTAT3 expression in circulating CD4+ T cells from CIS patients favors the early conversion to clinically defined multiple sclerosis
Howe et al. Functional heterogeneity among CD4+ T-cell clones from blood and skin lesions of leprosy patients. Identification of T-cell clones distinct from Th0, Th1 and Th2.
CN114791411A (en) Index combination, kit and method for evaluating human immune function
WO2020122405A1 (en) Composition for preventing or treating inflammatory diseases, comprising mesenchymal stem cells derived from dedifferentiated stem cells

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17770629

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 17770629

Country of ref document: EP

Kind code of ref document: A2